Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cadranel

Showing results (621-630 of 709) with videos related to

Pageof 71
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France projectMichèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Respiration; International Review of Thoracic Diseases|September 13, 2021
Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD CohortVincent Cottin, Sonia Gueguen, Stéphane Jouneau, et al.
Neurology|August 10, 2018
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Oncoimmunology|May 17, 2017
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapyHélène Roussel, Eléonore De Guillebon, Lucie Biard, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
American Journal of Human Genetics|June 16, 2015
RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial SpokesLudovic Jeanson, Bruno Copin, Jean-François Papon, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
European Radiology|November 19, 2025
CT features of interstitial lung disease in systemic lupus erythematosus and overlap lupus-other connective tissue diseaseAurore Sajust de Bergues de Escalup, Arthur Mageau, Lou Deneuville, et al.
Pageof 71

Showing results (621-630 of 709) with videos related to

Sort By:
Pageof 71
Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France projectMichèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Respiration; International Review of Thoracic Diseases|September 13, 2021
Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD CohortVincent Cottin, Sonia Gueguen, Stéphane Jouneau, et al.
Neurology|August 10, 2018
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Oncoimmunology|May 17, 2017
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapyHélène Roussel, Eléonore De Guillebon, Lucie Biard, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
American Journal of Human Genetics|June 16, 2015
RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial SpokesLudovic Jeanson, Bruno Copin, Jean-François Papon, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
European Radiology|November 19, 2025
CT features of interstitial lung disease in systemic lupus erythematosus and overlap lupus-other connective tissue diseaseAurore Sajust de Bergues de Escalup, Arthur Mageau, Lou Deneuville, et al.
Pageof 71